Dr. Chen Suen is a Program Director in the Prostate and Urologic Cancer Research Group (PUCRG). Before joining the NCI, Dr. Suen was a senior research advisor at Lilly Research Laboratories. He graduated from the School of Pharmacy, Taipei Medical University in Taiwan, and received a Ph.D., with distinction, from the Department of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine in New York City. Subsequently, he was awarded a postdoctoral fellowship from Howard Hughes Medical Institute (HHMI) and trained in the Division of Genetics, Department of Medicine at Brigham’s and Women Hospital, Harvard Medical School.
Dr. Suen spent 20 years in the pharmaceutical industry, including Wyeth-Ayers Research, Bristol-Myers Squibb, and Lilly Research Laboratories. He was deeply involved in the discovery and clinical development of novel molecules/medicine in cancer, immunology, inflammation, and endocrine diseases.
As a Program Director at NCI, Dr. Suen oversees a wide variety of research grants focusing on cancer prevention and translational medicine. Dr. Suen’s research interests include cancer drug discovery/development, pharmacology/toxicology, tumor immunology, and cancer vaccines.